HCA
HRMY icon

Harbor Capital Advisors’s Harmony Biosciences HRMY Stock Holding History

Harbor Capital Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-229
Closed -$7K – 1408
2025
Q2 		$7K Buy
229
+18
+9% +$579 ﹤0.01% 1069
2025
Q1 		$7K Buy
211
+1
+0.5% +$36 ﹤0.01% 1074
2024
Q4 		$7K Sell
210
-3
-1% -$103 ﹤0.01% 1053
2024
Q3 		$9K Buy
+213
New +$7.48K ﹤0.01% 1011

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbor Capital Advisors's HRMY Position: Q3 2025 in Review

Harbor Capital Advisors sold out of Harmony Biosciences (HRMY) in Q3 2025, closing a stake of 229 shares — an estimated $7K sold.

Harbor Capital Advisors first reported a position in HRMY in Q3 2024 and held it in 4 quarters. The position peaked at $9K in Q3 2024. 296 funds tracked by Wall St. Rank hold HRMY as of Q3 2025.

  • Harbor Capital Advisors reported no remaining Harmony Biosciences position as of Q3 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 229 Harmony Biosciences shares in Q3 2025, an estimated $7K.
  • Harbor Capital Advisors first reported a position in Harmony Biosciences in Q3 2024 and held it in 4 quarters.
  • Harbor Capital Advisors's Harmony Biosciences position peaked at $9K in Q3 2024.
  • 296 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2025.

Based on Harbor Capital Advisors's 13F filing for Q3 2025, filed 15 Oct 2025.